Ensysce Biosciences

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Answers Recently Asked Questions SAN DIEGO, CA / ACCESSWIRE / February 23, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick, to address the Company's most recent frequently asked questions. Dear Fellow Shareholders, As a clinical stage biotech company working through clinical development, our opportunities to touch base with our investor community are largely tied to Company milestones and the announcement of associated clinical data.

Ensysce Biosciences Provides Corporate Update

SAN DIEGO, CA / ACCESSWIRE / February 14, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced a Poster Presentation will be presented by Geoff Birkett, Chief Commercial Officer of Ensysce, at the Annual NIH HEAL Meeting on February 22, 2023, in Washington, D.C. The HEAL initiative is an effort to improve prevention and treatment strategies for opioid misuse and addiction and to enhance pain management across NIH institutes.

Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting

SAN DIEGO, CA / ACCESSWIRE / February 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-market under NASDAQ rules. In addition, in a concurrent private placement, the Company issued warrants to purchase up to 3,571,431 shares of common stock.

Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules

SAN DIEGO, CA / ACCESSWIRE / February 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has entered into a definitive agreement for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-marked under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue warrants to purchase up to 3,571,431 shares of common stock.

Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering

SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023.

Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

~ PF614-MPAR to be the Industry's First Overdose Protection Pain Product ~ SAN DIEGO, CA / ACCESSWIRE / January 25, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the initiation of the final stage of the Phase 1 study of PF614-MPAR. PF614-MPAR is the overdose protectionversion of its lead product, PF614, and this keystudy is being conducted in healthy subjects by Dr. Maria Bermudez MD, at Quotient Sciences, Miami, Florida.

Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

SAN DIEGO, CA / ACCESSWIRE / January 23, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Chief Executive Officer, Dr. Lynn Kirkpatrick, will present a company overview at the Diamond Equity Research 2023 Virtual Emerging Growth Invitational on Wednesday, January 25th, 2023, at 12:20 p.m. Eastern Time.

Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational

SAN DIEGO, CA / ACCESSWIRE / January 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick. Dear Fellow Shareholders, I want to take this opportunity to thank our shareholders for their continued support in 2022.

Ensysce Biosciences Issues 2023 Shareholder Letter

Data Expected in March 2023 SAN DIEGO, CA / ACCESSWIRE / January 4, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has successfully completed the clinical portion of study PF614-104, ‘A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared with Oxycodone Immediate-Release Tablets, and Placebo in Non-Dependent Recreational Opioid Users' (ClinicalTrials.gov: NCT05571345) being conducted by Dr. Vince Clinical Research. This is the second human abuse potential (HAP) study completed for PF614, a controlled-release oxycodone TAAPä prodrug, following completion of an intranasal HAP study in August 2022.

Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

AGM Group Holdings Inc - Ordinary Shares - Class A

Assembly Biosciences

Innate Pharma SA

LianBio

Soleno Therapeutics

Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 6 To Watch With Big News Today

~ PF614-MPAR will be the Industry's First Overdose Protection Pain Product ~ SAN DIEGO, CA / ACCESSWIRE / December 19, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced data demonstrating the overdose protection of its drug product, PF614-MPAR from the clinical study being conducted in Healthy Subjects by Dr. Maria Bermudez MD, at Quotient Sciences, Miami, Florida. PF614-MPAR is designed to provide optimal pain relief at prescribed doses.

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

The stock price of Ensysce Biosciences (ENSC) plummeted over 50% intraday today. This is why.

Ensysce Biosciences (ENSC) Plummets Over 50%: Details

SAN DIEGO, CA / ACCESSWIRE / December 7, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the pricing of an underwritten public offering of 2,900,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 5,800,000 shares of common stock at a combined effective public offering price of $1.40 per share of common stock (or pre-funded warrant) and accompanying warrants. Each warrant is exercisable immediately at an exercise price of $1.40 per share and will expire five years following the date of issuance.

Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering

~ Completion of Trial Represents Continuing Progress Towards Development of the Industry's First Overdose Protection Pain Product ~ SAN DIEGO, CA / ACCESSWIRE / December 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC),(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has successfully completed the clinical portion of study PF614-MPAR-101 Part A, entitled ‘Single-Dose Study to Evaluate the Pharmacokinetics of oxycodone and PF614, when PF614 Solution is Co-Administered with Nafamostat, as an Immediate-Release Solution and/or Extended-Release (ER) Capsule Formulations in Healthy Subjects', being conducted by Dr. Maria Bermudez MD, at Quotient Sciences, Miami Florida. Dr. Lynn Kirkpatrick, CEO of Ensysce, commented, "Overdose with opioids is a societal crisis.

Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

CytomX Therapeutics

NeuroOne Medical Technologies Corp

Nexalin Technology Inc

Taysha Gene Therapies

Biotech penny stocks to watch this week. Are they a buy now?

Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week

Corporate Update Call to be Held Wednesday, November 16, 2022 SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today reported financial results for the third quarter of 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We remain focused on progressing our clinical development plans for our programs and achieving each milestone we have identified.

Ensysce Biosciences Reports Third Quarter 2022 Financial Results

Ardelyx

Nokia

Opendoor

How To Play "The Stock Market Game" With Penny Stocks & What To Watch This Week. The post 4 Penny Stocks To Watch If You're Playing “The Stock Market Game” appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch If You're Playing “The Stock Market Game”

~ Acute pain indication may be appropriate, with potential to significantly shorten development path ~ SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced that it received written guidance from the FDA that an acute pain indication may be appropriate for the Company's lead Trypsin Activated Abuse Protection (TAAPTM) product, PF614. The FDA guidance, while not binding, states that the Company's proposed clinical development approach of conducting at least two adequate and well-controlled clinical trials in two different pain models comparing PF614 to placebo and to another immediate release (IR) opioid, such as IR oxycodone, appears reasonable to support a new drug application for PF614 for an acute pain indication.

Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614

~ Announces Timing of Corporate Update Call ~ SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced positive topline results from a human abuse potential (HAP) study for PF614. PF614 is a new class of analgesia, a Trypsin Activated Abuse-Protected oxycodone product.

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product

~ Critical Study to Support Abuse Deterrent Labeling ~ SAN DIEGO, CA / ACCESSWIRE / October 28, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced the first subjects dosed in the PF614-104 study, ‘A Randomized, Double-blind, Placebo and Active-Controlled, Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared with Oxycodone Immediate-Release Tablets, and Placebo in Non-Dependent Recreational Opioid Users' (ClinicalTrials.gov Identifier: NCT05571345). The study is being conducted by Drs.

Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study

San Diego, California--(Newsfile Corp. - October 12, 2022) - Ensysce Biosciences, Inc. (NASDAQ: ENSC) (OTC Pink: ENSCW) ("Ensysce" or the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced management's participation in the LD Micro Main Event XV conference being held from October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Bel Air, California.The Company's Chief Executive Officer, Dr.

Ensysce Biosciences, Inc. Announces Participation in LD Micro Main Event XV Conference

~ Oral Opioid Abuse Being Explored for PF614 ~ ~ Data From Trial Supports Abuse Deterrent Labeling, Designed to Measure the Potential for Drug Liking ~ SAN DIEGO, CA / ACCESSWIRE / September 22, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced the initiation of PF614-104, ‘A Randomized, Double-blind, Placebo and Active-Controlled, Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared with Oxycodone Immediate-Release Tablets, and Placebo in Non-Dependent Recreational Opioid Users.' The study is being conducted by Dr. Brad Vince, from Dr. Vince Clinical Research (DVCR), at one of the most innovative and technologically advanced clinical pharmacology units, newly constructed and recently opened in Overland Park, Kansas.

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

SAN DIEGO, CA / ACCESSWIRE / September 21, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that management will present during Benzinga's All Access investor event taking place Friday, September 23, 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, is scheduled to host a presentation and Q&A session during the event as follows.

Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022

SAN DIEGO, CA / ACCESSWIRE / September 8, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the results of the special meeting of stockholders held September 8, 2022. This meeting was held virtually, and the following resolutions were submitted and adopted by the stockholders: The approval of, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance and exercise of shares of common stock issued by the Company to certain investors.

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

~ Special Meeting to be Held Virtually on Thursday, September 8th at 9:00 AM PT ~ SAN DIEGO, CA / ACCESSWIRE / September 6, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today reminds shareholders to vote on or before the upcoming annual shareholder meeting on Thursday, September 8th at 9:00 AM PT/12:00 PM ET. This meeting will be held virtually, using the weblink https://agm.issuerdirect.com/ensc, for the following purposes: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance and exercise of shares of common stock issued by the Company to certain investors.

News for Ensysce Biosciences Stock (ENSC)